An observational study in Critical Illness and Muscle Atrophy, sponsored by Guy's and St Thomas' NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by Guy's and St Thomas' NHS Foundation Trust · Observational
Among 52 studies in Muscular Atrophy with a site in United Kingdom — 7 open to participants now, 11 under way, 2 of them phase 3. Muscular Atrophy · United Kingdom.
Among the 52 studies in Muscular Atrophy with a site in United Kingdom, this one has the largest enrollment of the 10 observational ones that give a count, is one of 7 that started in 2017, is one of 10 observational ones, and was the 18th registered.
413 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.
Browse Muscular Atrophy studies →7 of the 52 studies in Muscular Atrophy with a site in United Kingdom are open now. Recruiting first, the newest first:
MSK Doctors & Associates Ltd · Sites in United Kingdom
Ages 18+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
University of Nottingham · Sites in United Kingdom
Ages 18+
University of Bath · Sites in United Kingdom
Ages 65–85 · Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 50–90 · Men only · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 12 (24%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 7
First in 2009; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 215 is above the median of 61 across 73 observational studies indexed under Muscular Atrophy.
Median enrollment 30 across the 42 interventional studies, 29 across the 10 observational. Of the 33 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 52 have an industry lead sponsor. The 10 most frequent:
Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.
Guy's and St Thomas' NHS Foundation Trust has 3 studies filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
2 of the studies in Muscular Atrophy with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06964438University of NottinghamPostoperative Electrical Muscle Stimulation Two | 2027-02-01 |
| NCT05414292University of NottinghamImpacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune) | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Muscular Atrophy with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a retrospective, observational study and will investigate the clinical predictive value of and change in muscle quantity and quality in critically ill patients with severe respiratory failure requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO).
The use of veno-venous extra-corporeal membrane oxygenation (VV-ECMO) for severe respiratory failure - mainly hypoxaemia - has increased over recent years. Similar to the general population in the Intensive Care Unit (ICU), these patients become deconditioned, severely weak (ICU acquired weakness- ICUAW) and require prolonged rehabilitation after disconnection from VV-ECMO. However, data regarding the magnitude of muscle wasting and recovery in this specific group is lacking.
Both poor muscle quantity and quality have been found to be a predictor or poor outcome. As all patients receiving VV-ECMO at our hospital will get an initial CT scan of their chest, abdomen and pelvis, these CT scans will be used to measure muscle quantity and quality of different muscle groups of the abdomen at admission and then using any follow-up CT scan performed within 10 days. In addition, the relationship between the loss of muscle over the course of VV-ECMO and perceived recovery of renal function at ICU discharge will be investigated.
413 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.
This study's enrollment of 215 is above the median of 61 across 73 observational studies indexed under Muscular Atrophy.
Browse Muscular Atrophy studies →Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.
Compared within Muscular Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult Critically ill patients with severe respiratory failure requiring VV-ECMO
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All cause mortality
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: On ECMO (expected to be about 10 days)
Length of ECMO duration
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: The total duration on ECMO (expected to be an average of 10 days)
Length of ICU admission
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: The total duration of ICU admission (expected to be around 2 weeks)
Length of hospital stay
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: The total duration of hospital admission (expected to be around 28 days)
Length of ventilation
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: Total duration of mechanical ventilation during intensive care unit stay (expected to be around 10 days)
Discharge destination
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: After discharge from hospital (expected to be around 28 days)
Sequential changes in the muscle quantity over time
Using total muscle quantity measured from CT slice of the third lumbar region.
Time frame: The total duration of ECMO (expected to be around 10 days)
Sequential changes in muscle quality over time
Using total muscle quality measured from CT slice of the third lumbar region.
Time frame: The total duration of ECMO (expected to be around 10 days)
Relationship between muscle loss and total nutrition received
Using total muscle quantity measured from CT slice of the third lumbar region.
Time frame: The total duration of ECMO (expected to be around 10 days)
Relationship between muscle loss and rehabilitation goals met
Using total muscle quantity measured from CT slice of the third lumbar region.
Time frame: The total duration of ECMO (expected to be around 10 days)
All cause mortality
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: Intensive Care Unit Stay (expected to be about 2 weeks)
All cause mortality
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: 6 months post-ICU discharge
All cause mortality
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
Time frame: Hospital discharge (expected to be about 28 days)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2017 to primary completion in May 2018, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guy's and St Thomas' NHS Foundation Trust →